{"id":"https://openalex.org/W347227128","doi":"https://doi.org/10.1007/978-3-0348-7276-8_5","title":"Mediation of Inflammation by Cyclooxygenase-2","display_name":"Mediation of Inflammation by Cyclooxygenase-2","alternate_titles":[],"publication_year":1995,"publication_date":"1995-01-01","ids":{"openalex":"https://openalex.org/W347227128","doi":"https://doi.org/10.1007/978-3-0348-7276-8_5","mag":"347227128","pmid":"https://pubmed.ncbi.nlm.nih.gov/7610990"},"language":"en","primary_location":{"id":"doi:10.1007/978-3-0348-7276-8_5","doi":"https://doi.org/10.1007/978-3-0348-7276-8_5","is_oa":false,"landing_page_url":"https://doi.org/10.1007/978-3-0348-7276-8_5","pdf_url":null,"source":{"id":"https://openalex.org/S4306462920","display_name":"Birkh\u00e4user Basel eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Novel Molecular Approaches to Anti-Inflammatory Therapy","raw_type":"book-chapter"},"parent_works":[{"id":"https://openalex.org/W642333977","display_name":"Novel Molecular Approaches to Anti-Inflammatory Therapy","relationship":"volume","link_type":"volume"}],"lineage":["https://openalex.org/W347227128","https://openalex.org/W642333977"],"child_works_count":0,"type":"book-chapter","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113754834","display_name":"Karen Seibert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karen Seibert","raw_affiliation_strings":["G. D. Searle and Monsanto Corporate Research, St. Louis, Missouri 63167, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"G. D. Searle and Monsanto Corporate Research, St. Louis, Missouri 63167, USA","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045236281","display_name":"Jaime L. Masferrer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jaime Masferrer","raw_affiliation_strings":["Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100456297","display_name":"Yan Zhang","orcid":"https://orcid.org/0000-0002-7017-5186","observed_orcids":["https://orcid.org/0000-0002-7017-5186"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yan Zhang","raw_affiliation_strings":["Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111767726","display_name":"Susan A. Gregory","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Susan Gregory","raw_affiliation_strings":["Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065266616","display_name":"Gary L. Olson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gary Olson","raw_affiliation_strings":["Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112257473","display_name":"Scott D. Hauser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Scott H\u00e4user","raw_affiliation_strings":["Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kathleen Leahy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kathleen Leahy","raw_affiliation_strings":["Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111906030","display_name":"William J. Perkins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"William Perkins","raw_affiliation_strings":["Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027639379","display_name":"Peter C. Isakson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Peter Isakson","raw_affiliation_strings":["Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":17.7722,"has_fulltext":false,"cited_by_count":163,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.99141631,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"46","issue":null,"first_page":"41","last_page":"50"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12910","display_name":"Eicosanoids and Hypertension Pharmacology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cyclooxygenase-2","display_name":"cyclooxygenase-2","score":0.9990000128746033},{"id":"https://openalex.org/keywords/inflammation","display_name":"inflammation","score":0.6880000233650208},{"id":"https://openalex.org/keywords/nonsteroidal-anti-inflammatory-drugs","display_name":"nonsteroidal anti-inflammatory drugs","score":0.9570000171661377},{"id":"https://openalex.org/keywords/cox-1","display_name":"cyclooxygenase-1","score":0.890999972820282},{"id":"https://openalex.org/keywords/cox-2-inhibitors","display_name":"COX-2 inhibitors","score":0.8450000286102295},{"id":"https://openalex.org/keywords/prostaglandins","display_name":"prostaglandins","score":0.8920000195503235},{"id":"https://openalex.org/keywords/arachidonic-acid-metabolism","display_name":"arachidonic acid metabolism","score":0.9210000038146973},{"id":"https://openalex.org/keywords/nsaid-adverse-effects","display_name":"NSAID adverse effects","score":0.878000020980835},{"id":"https://openalex.org/keywords/gastrointestinal-toxicity","display_name":"gastrointestinal toxicity","score":0.7720000147819519},{"id":"https://openalex.org/keywords/indomethacin","display_name":"indomethacin","score":0.8289999961853027}],"concepts":[{"id":"https://openalex.org/C2779689624","wikidata":"https://www.wikidata.org/wiki/Q410251","display_name":"Cyclooxygenase","level":3,"score":0.8296822309494019},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.6937627792358398},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6527221202850342},{"id":"https://openalex.org/C2778078955","wikidata":"https://www.wikidata.org/wiki/Q407699","display_name":"Arachidonic acid","level":3,"score":0.5749842524528503},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5236865282058716},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.46855148673057556},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.29581189155578613},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2469332218170166},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.18097639083862305}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000894","descriptor_name":"Anti-Inflammatory Agents, Non-Steroidal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D001169","descriptor_name":"Arthritis, Experimental","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D001169","descriptor_name":"Arthritis, Experimental","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D005767","descriptor_name":"Gastrointestinal Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D007527","descriptor_name":"Isoenzymes","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D011451","descriptor_name":"Prostaglandin-Endoperoxide Synthases","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D016861","descriptor_name":"Cyclooxygenase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/978-3-0348-7276-8_5","doi":"https://doi.org/10.1007/978-3-0348-7276-8_5","is_oa":false,"landing_page_url":"https://doi.org/10.1007/978-3-0348-7276-8_5","pdf_url":null,"source":{"id":"https://openalex.org/S4306462920","display_name":"Birkh\u00e4user Basel eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Novel Molecular Approaches to Anti-Inflammatory Therapy","raw_type":"book-chapter"},{"id":"pmid:7610990","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7610990","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Agents and actions. Supplements","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1485442945","https://openalex.org/W1488753908","https://openalex.org/W1508152421","https://openalex.org/W1536681507","https://openalex.org/W1590259662","https://openalex.org/W1601845527","https://openalex.org/W1981819970","https://openalex.org/W1997364548","https://openalex.org/W2008574207","https://openalex.org/W2014007136","https://openalex.org/W2015371826","https://openalex.org/W2033255776","https://openalex.org/W2077459776","https://openalex.org/W2113745276","https://openalex.org/W2115350007","https://openalex.org/W2122355853","https://openalex.org/W2134732424","https://openalex.org/W2146540723","https://openalex.org/W2146605723","https://openalex.org/W2147185712","https://openalex.org/W4205395497"],"related_works":["https://openalex.org/W2293977658","https://openalex.org/W100269779","https://openalex.org/W122911005","https://openalex.org/W2083748640","https://openalex.org/W2159859519","https://openalex.org/W2017917394","https://openalex.org/W2321877600","https://openalex.org/W2261949516","https://openalex.org/W130440447","https://openalex.org/W2189651229"],"abstract_inverted_index":{"Non-steroidal":[0],"antiinflammatory":[1,46],"drugs":[2],"(NSAIDs)":[3],"are":[4,18,44,88],"commonly":[5],"used":[6],"for":[7],"the":[8,25,31,37,80,93,111,116],"treatment":[9],"of":[10,24,33,57,92,98,110,118,124],"inflammation,":[11],"pain,":[12],"and":[13,65,77],"fever.":[14],"Mechanistically,":[15],"these":[16],"compounds":[17],"believed":[19],"to":[20,36,90],"act":[21],"via":[22],"inhibition":[23,91,109],"enzyme":[26],"cyclooxygenase":[27],"(COX),":[28],"which":[29],"catalyzes":[30],"conversion":[32],"arachidonic":[34],"acid":[35],"prostaglandins":[38],"(PGs).":[39],"Although":[40],"commercially":[41],"available":[42,70,137],"NSAIDS":[43],"efficacious":[45],"agents,":[47],"significant":[48,133],"side":[49],"effects":[50],"limit":[51],"their":[52],"use.":[53],"Recently":[54],"two":[55],"forms":[56],"COX":[58,99],"were":[59],"identified-":[60],"a":[61,66,121,132],"constitutively":[62],"expressed":[63],"COX-1":[64,76],"cytokine-inducible":[67],"COX-2.":[68],"Commercially":[69],"NSAIDs":[71],"like":[72],"indomethacin":[73],"inhibit":[74],"both":[75],"COX-2":[78,125],"suggesting":[79],"hypothesis":[81],"that":[82],"toxicities":[83],"associated":[84],"with":[85],"NSAID":[86],"therapy":[87],"due":[89],"non-regulated":[94],"or":[95],"constitutive":[96],"form":[97],"(COX-1)":[100],"in":[101],"normal":[102],"tissues,":[103],"whereas":[104],"therapeutic":[105],"benefit":[106],"derives":[107],"from":[108],"inducible":[112],"enzyme,":[113],"COX-2,":[114],"at":[115],"site":[117],"inflammation.":[119],"Therefore,":[120],"selective":[122],"inhibitor":[123],"may":[126],"be":[127],"anti-inflammatory":[128],"without":[129],"GI":[130],"toxicity-providing":[131],"improvement":[134],"over":[135],"currently":[136],"NSAIDs.":[138]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W347227128","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":4},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
